serum a-fabp is increased and closely associated with elevated nt-probnp levels in type 2 diabetic patients treated with rosiglitazone血清a-fabp增加和与中位数水平以上病人水平升高密切相关与罗格列酮治疗2型糖尿病患者.pdfVIP

Serum A-FABP Is Increased and Closely Associated with Elevated NT-proBNP Levels in Type 2 Diabetic Patients Treated with Rosiglitazone 1,2 2 2 2 2 Mi Zhou , Yuqian Bao , Junxi Lu , Jian Zhou , Weiping Jia * 1 Department of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2 Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai Clinical Center for Diabetes, Shanghai, China Abstract Background: Adipocyte fatty acid-binding protein (A-FABP) has been shown to play important roles in the development of metabolic syndrome, diabetes, and cardiovascular diseases. In this study we investigated the possible role of A-FABP in the development of cardiac dysfunction related to rosiglitazone treatment. Methodology/Principal Findings: A total of 84 patients with newly diagnosed type 2 diabetes were treated with rosiglitazone for 48 weeks. Circulating A-FABP and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were determined at baseline and repeated at 24 and 48 weeks. After the 48-week rosiglitazone treatment period, serum levels of both A-FABP and NT-proBNP increased progressively and significantly (P,0.01). Serum levels of A-FABP were demonstrated to be positively correlated with gender and waist circumference both at baseline and the end of the study, and with age, body mass index (BMI), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and NT-proBNP at 48 weeks (all P,0.05). In addition, changes in A-FABP were significantly and positively correlated with changes in NT- proBNP (r = 0.239, P = 0.039). Furthermore,